EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Correlations between plasma markers and brain Aβ deposition across the AD continuum: Evidence from SILCODE

Xianfeng Yu, Rong Shi, Xia Zhou, Mingkai Zhang, Yue Cai, Jiehui Jiang, Ying Han

Alzheimer's & Dementia · 2024-09 · 20 (9) · 6170-6182

DOI: 10.1002/alz.14084 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 10.07.2024. Verfasst von Xianfeng Yu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Biomarkers, Brain. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: STI2030-Major Projects, NSFC, Sino-German Cooperation Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Previous studies have found that Alzheimer's disease (AD)‐related plasma markers are associated with amyloid beta (Aβ) deposition, but the change of this association in different Aβ pathological stages remains unclear. METHODS Data were obtained from the SILCODE. According to the standardized uptake value ratio (SUVR) and Aβ stage classification, correlation analysis was performed among plasma biomarkers, and voxel/SUVR values in the regions of interest (ROI) and clinical scale information, respectively. Mediation analysis was used to study the possible pathways. RESULTS The proportion of cognitively normal (CN) and subjective cognitive decline (SCD) was the highest in stages A0 to 1, while in stages A2 to 4, the proportion of mild cognitive impairment (MCI) and AD increased. Plasma phosphorylated tau (p‐tau)181 and glial fibrillary acidic protein (GFAP) levels were significantly lower in stage A0 compared to the later phases. Two pathways demonstrated fully mediated effects: positron emission tomography (PET) SUVR–plasma p‐tau181–Mini‐Mental State Examination (MMSE) and PET SUVR–plasma GFAP–MMSE. DISCUSSION This study demonstrated the role of plasma biomarkers in the early stage of AD, especially in SCD, from both the clinical diagnosis and Aβ stage dimensions. Highlights Plasma ptau181 and GFAP level serve as indicators of early Alzheimer's disease and the pathologic Aβ staging classification. A possible ceiling effect of GFAP was observed in the mid‐to‐late stages of the AD course. This study confirms the role of AD plasma markers in promoting Aβ deposition at an early stage, particularly in females with subjective cognitive decline(SCD). The overlapping brain regions of plasma p‐tau181, GFAP, and neurofilament light for Aβ deposition in the brain in early AD were distributed across various regions, including the posterior cingulate gyrus, rectus gyrus, and inferior temporal gyrus.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersBrainCognitive DysfunctionAgedAged, 80 and overFemaleHumansMaleGlial Fibrillary Acidic ProteinPositron-Emission Tomographytau Proteins

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid beta positron emission tomographybiomarkerplasmasubjective cognitive decline

Substanzen

Amyloid beta-PeptidesBiomarkersGFAP protein, humanGlial Fibrillary Acidic Proteintau Proteins

Autor:innen und Institutionen

  • Department of Neurology, Xuanwu Hospital of Capital Medical University, Beijing, China.
  • Department of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • School of Information and Communication Engineering, Shanghai University, Shanghai, China.
  • Institute of Biomedical Engineering, Shenzhen Bay Laboratory, Shenzhen, China.
  • Institute of Biomedical Engineering, School of Life Sciences, Shanghai University, Shanghai, China.
  • School of Biomedical Engineering, Hainan University, Haikou, China.

Förderung

  • STI2030-Major Projects
  • NSFC
  • Sino-German Cooperation Grant
  • Shenzhen Bay Scholars Program
  • Tianchi Scholars Program
  • National Natural Science Foundation of China

Zitieren

APA

Yu, X., Shi, R., Zhou, X., Zhang, M., Cai, Y., Jiang, J., & Han, Y. (2024). Correlations between plasma markers and brain Aβ deposition across the AD continuum: Evidence from SILCODE. Alzheimer's & Dementia, 20(9), 6170-6182. https://doi.org/10.1002/alz.14084

Vancouver

Yu X, Shi R, Zhou X, Zhang M, Cai Y, Jiang J, et al. Correlations between plasma markers and brain Aβ deposition across the AD continuum: Evidence from SILCODE. Alzheimer's & Dementia. 2024;20(9):6170-6182. doi:10.1002/alz.14084

BibTeX
@article{Yu2024,
  author = {Yu, Xianfeng and Shi, Rong and Zhou, Xia and Zhang, Mingkai and Cai, Yue and Jiang, Jiehui and Han, Ying},
  title = {Correlations between plasma markers and brain Aβ deposition across the AD continuum: Evidence from SILCODE},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  volume = {20},
  number = {9},
  pages = {6170--6182},
  doi = {10.1002/alz.14084}
}
Kostenlos starten →